An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

This open-label trial (n=10) will examine low-dose psilocybin as a safe treatment alternative for Fragile X Syndrome (FXS), aiming to improve markers of cognition, communication, mood, behaviour, neuroinflammation, serotonin levels in exosomes, and neuroplasticity.

The study will assess the feasibility of psilocybin as a therapeutic option for individuals with FXS and improve diagnostic parameters and therapeutic responses using biomarkers. Participants will undergo screening, baseline assessments, and follow-up visits on days 8, 15, 22, and 28 to complete various clinician and self-report assessments, digital assessments and saliva/buccal swab collection.

Topic Autism
Compound Psilocybin
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Nova Mentis
Nova Mentis is a Canadian listed (CSE, FSE) company that holds two subsidiaries, Nova Mentis Biotech and Pilz BioSciences that investigate psychedelics as medicines for a variety of mental health indicators.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.